02:45 PM EDT, 07/31/2025 (MT Newswires) -- AbbVie ( ABBV ) is in talks to acquire Gilgamesh Pharmaceuticals in a deal that could value the psychedelics developer at about $1 billion, Bloomberg reported Thursday, citing people familiar with the matter.

The potential deal comes a year after AbbVie ( ABBV ) and Gilgamesh entered into a collaboration to develop next-generation psychedelics for mental health conditions, according to the report.

An announcement could be made in the coming weeks, Bloomberg said, adding that deliberations are ongoing and could be delayed or fall apart.

AbbVie ( ABBV ) did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 189.12, Change: -0.19, Percent Change: -0.10